Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to second-line eltrombopag prolonged time to treatment failure by more than 40%. Researchers ...

SAN DIEGO -- Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...

A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ...

There are no widely available therapies approved for this indication ...